Pegargiminase

other

Identifier: CI-DRUG-00000461
Entity page: /drug/pegargiminase ↗
Edges: 71

Neighbours: 21 cancers1 variants10 trials
Drawn: 32 of 32 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pegargiminase predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	ASS1 UNDEREXPRESSIONexpression	sensitivity	D	Sarcoma	1	Curated	civic	graph →
Pegargiminase investigated for …INVESTIGATED_FOR14 of 14
→ investigated for

Pegargiminase investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 23show all (up to 200)
→ investigated in trials for	Hepatocellular Carcinomasubtype 9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastomasubtype 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Soft Tissue Sarcoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Soft Tissue Sarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Uveal Melanomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Uveal Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Myeloid Leukemia 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Midline Glioma, H3 K27M-Mutant 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Midline Glioma, H3 K27M-Mutant	1	Observed	clinicaltrials	graph →
→ investigated in trials for	High-Grade Glioma, NOS 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High-Grade Glioma, NOS	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Squamous Non-Small Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Pegargiminase investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 23show all (up to 200)

→ investigated in trials for

Hepatocellular Carcinomasubtype

9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hepatocellular Carcinoma

Observed

Pegargiminase studied in …STUDIED_INderived10 of 33show all (up to 200)
→ studied in	NCT06085729Phase 1/Phase 2 · recruiting Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) · 33 trials list this drug (6 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07389278Phase 1/Phase 2 · not yet recruiting Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) · 33 trials list this drug (6 active)	—	—	Glioblastoma,Glioma,Diffuse Midline Glioma, H3 K27M-Mutant+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT05813327Phase 1 · terminated Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma · 33 trials list this drug (6 active)	—	—	Soft Tissue Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03970447Phase 2/Phase 3 · recruiting A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma · 33 trials list this drug (6 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05616624Phase 1/Phase 2 · terminated ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers · 33 trials list this drug (6 active)	—	—	Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05712694Phase 3 · terminated Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) · 33 trials list this drug (6 active)	—	—	Soft Tissue Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05001828Phase 1 · active not recruiting Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia · 33 trials list this drug (6 active)	—	—	Adult Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05317819Phase 3 · recruiting Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma · 33 trials list this drug (6 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03449901Phase 2 · completed ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer · 33 trials list this drug (6 active)	—	—	Soft Tissue Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04587830Phase 2 · active not recruiting ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme · 33 trials list this drug (6 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths